KinoPharma is a next-generation antiviral drug development company that focuses on providing new antiviral drugs for the treatment of Papillomavirus (HPV) infections, which are the cause of cervical cancer. They are dedicated to offering these drugs as early as possible, aiming to save lives and prevent the need for surgical interventions. With a research and development strategy based on innovative drug creation, KinoPharma is committed to addressing medical needs in high-demand disease areas, particularly those related to viral infections.

Their approach to developing next-generation antiviral drugs deviates from traditional strategies, ensuring they stay at the forefront of medical advancements. By providing low-molecular-weight drugs based on a novel drug discovery approach, KinoPharma strives to deliver efficient and effective treatments to patients worldwide